Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/7/2026

Acromegaly Medical Therapy Guidelines

Established Medical Therapies

  • The American College of Endocrinology recommends somatostatin receptor ligands (SRLs) as the primary first-line medical therapy after unsuccessful surgery, with long-acting octreotide and lanreotide showing equivalent efficacy in normalizing GH and IGF-I levels in approximately 25-60% of patients 1.
  • No evidence demonstrates a difference in efficacy between long-acting lanreotide and octreotide formulations, according to the Endocrine Society 1, 2.
  • For partial responders to SRLs, combination therapy with pegvisomant plus SRL should be considered, as recommended by the American Association of Clinical Endocrinologists 1, 3.
  • Cabergoline may be considered as primary therapy in patients with mild disease (IGF-I <2 × upper limit of normal), as suggested by the European Society of Endocrinology 1, 2.

Novel and Emerging Therapies

  • Oral octreotide capsules represent the first oral SRL approved in the United States, using transient permeability enhancer technology to enable gut absorption, according to the FDA 2, 3.
  • An antisense oligonucleotide that binds to GH receptor mRNA and inhibits translation of the receptor protein is in early clinical development, as reported by the National Institutes of Health 2, 3.

Treatment Algorithm for Medical Therapy

  • Initiate long-acting SRL (octreotide LAR or lanreotide) at standard doses, as recommended by the American College of Endocrinology 1.
  • For SRL non-responders, switch to pegvisomant monotherapy, according to the Endocrine Society 1, 2.
  • For SRL partial responders, add pegvisomant to continue SRL therapy, as suggested by the American Association of Clinical Endocrinologists 1, 3.
  • Consider cabergoline as primary therapy if IGF-I <2 × upper limit of normal, as recommended by the European Society of Endocrinology 1, 2.
  • Lifelong monitoring of IGF-I levels must be maintained even if drug withdrawal is attempted in rare cases of persistent control, according to the National Institutes of Health 1, 3.

Acromegaly Treatment Guidelines

Introduction to Treatment Options

  • The Endocrine Society recommends surgery performed by an experienced neurosurgeon as the first-line treatment for acromegaly, offering the prospect of complete remission 4, 5
  • Transsphenoidal surgery is the preferred initial treatment for most patients, with surgical success rates of approximately 50% in experienced centers 4, 5

Medical Therapy

  • First-generation Somatostatin Receptor Ligands (SRLs), such as octreotide and lanreotide, are the drugs of choice for patients with persistent disease after surgery, achieving biochemical normalization in approximately 25% of unselected treatment-naive patients 6, 7
  • Cabergoline can be used as monotherapy in patients with mild GH excess or in combination with SRLs when GH hypersecretion is inadequately controlled, with best response occurring in patients with mildly elevated GH and IGF-I levels 4, 5, 6
  • Pegvisomant has well-established efficacy in normalizing IGF-I levels, with long-term safety data being reassuring, and requires ongoing monitoring of liver function and tumor size 6

Treatment Goals and Monitoring

  • The treatment goal is to normalize growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, reduce tumor size, and preserve vision, with regular monitoring of IGF-1 levels and repeat biochemical and radiological assessments 4, 5, 6, 8
  • Medical treatment of acromegaly with normalization of GH and IGF-I levels decreases mortality rates, and improves left ventricular hypertrophy, hypertension, and obstructive sleep apnea 7, 9, 10

Special Considerations

  • In patients with genetic causes of acromegaly, the whole pituitary gland may be affected, requiring different surgical approaches 4, 5
  • GH receptor antagonists like pegvisomant can effectively suppress growth velocity in children with gigantism 4, 5

Management of Acromegalic Arthropathy in Biochemically Controlled Patients

Pharmacologic Symptom Control

Physical Therapy

Therapeutic Escalation Considerations

Radiation Therapy & Surgical Timing

Management of Associated Comorbidities